Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prodrugs01:30

Prodrugs

2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

530
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
530
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

206
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
206
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

901
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
901
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

226
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
226
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

228
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CMR Reveals the Influence of Trigger and Classification on the Myocardial Tissue Response in Takotsubo Syndrome.

Circulation. Cardiovascular imaging·2026
Same author

Multimodality cardiovascular imaging in arrhythmic mitral valve prolapse: a state-of-the-art review from structural assessment to myocardial tissue characterization.

Frontiers in cardiovascular medicine·2026
Same author

[An unusual case of ST-segment elevation].

Giornale italiano di cardiologia (2006)·2026
Same author

Ventricular Repolarization Abnormalities in Pediatric Athletes: A Practical Approach to Clinical Evaluation.

Journal of cardiovascular development and disease·2026
Same author

Cardiac magnetic resonance-derived left atrioventricular coupling index predicts outcome in reduced ejection fraction.

ESC heart failure·2026
Same author

Insights Into the Natural History of Recurrent Myocarditis, A Multicenter International Study (Re-Myo Study).

Journal of the American Heart Association·2026
Same journal

Correction to: May Measurement Month 2017: screening for hypertension in Nigeria-Sub-Saharan Africa.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Optimizing protected PCI strategies in the setting of chronic kidney disease and advanced coronary artery disease: a clinical case-based discussion.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Patient selection for complex, high-risk indicated percutaneous coronary intervention procedures: an overview.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Protected percutaneous coronary intervention of complex distal left main disease with Impella CP™ support.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Impella™-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Contemporary evidence in protected percutaneous coronary intervention: a case-based review.

European heart journal supplements : journal of the European Society of Cardiology·2026
See all related articles

Related Experiment Video

Updated: Jul 31, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Bempedoic acid: what prospective uses?

Ilaria Jacomelli1, Luca Monzo1,2, Germana Panattoni1

  • 1Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|May 1, 2023
PubMed
Summary
This summary is machine-generated.

Bempedoic acid significantly lowers low-density lipoprotein cholesterol (LDL-c) in patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia. This new treatment offers a favorable safety profile when statins are insufficient.

Keywords:
Bempedoic acidCardiovascular diseaseLDL-cholesterolStatin intolerance

More Related Videos

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.8K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

Related Experiment Videos

Last Updated: Jul 31, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.8K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-c) remains a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Current lipid-lowering therapies, including statins, ezetimibe, and PCSK9 inhibitors, are often insufficient to achieve target LDL-c levels in high-risk patients.
  • Atherosclerotic cardiovascular disease and familial hypercholesterolemia necessitate advanced therapeutic strategies for effective LDL-c reduction.

Purpose of the Study:

  • To evaluate the efficacy of bempedoic acid in reducing LDL-c levels.
  • To assess the safety profile of bempedoic acid in diverse patient populations.
  • To determine the effectiveness of bempedoic acid as an add-on therapy when maximally tolerated statins fail to reach lipid goals.

Main Methods:

  • Clinical trials involving patients with ASCVD and/or familial hypercholesterolemia.
  • Administration of bempedoic acid to assess its impact on lipid profiles.
  • Monitoring of patient outcomes and adverse events to evaluate safety.

Main Results:

  • Bempedoic acid demonstrated a significant reduction in LDL-c across various patient groups.
  • The treatment was associated with a favorable safety profile.
  • Achieved substantial LDL-c lowering in patients who did not reach their goals with existing therapies.

Conclusions:

  • Bempedoic acid is an effective therapeutic option for lowering LDL-c in patients with ASCVD and familial hypercholesterolemia.
  • Its favorable safety profile makes it a valuable addition to the lipid-lowering armamentarium.
  • Bempedoic acid addresses an unmet need for effective treatments when standard therapies are inadequate.